Drug Trial Radar · NCT02960893
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Dec 15, 2016
Primary completion
Aug 18, 2017
Study completion Sep 20, 2024
Sponsor
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
Conditions
- Spinocerebellar Ataxias
- Spinocerebellar Ataxia Genotype Type 1
- Spinocerebellar Ataxia Genotype Type 2
- Spinocerebellar Ataxia Genotype Type 3
- Spinocerebellar Ataxia Genotype Type 6
- Spinocerebellar Ataxia Genotype Type 7
- Spinocerebellar Ataxia Genotype Type 8
- Spinocerebellar Ataxia Genotype Type 10
Interventions
TroriluzoleDrug
Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
PlaceboDrug
Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
TroriluzoleDrug
OLE phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) at Randomization Phase Week 8Time frame: Baseline, Randomization Phase Week 8
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
CNS Trial
Long Beach, California
University of California, Los Angeles
Los Angeles, California
University of California, San Francisco
San Francisco, California
University of Colorado Denver
Denver, Colorado
University of Florida
Gainesville, Florida
University of South Florida
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Harvard University (Massachusetts General Hospital)
Boston, Massachusetts
Harvard University (Beth Israel Deaconess Medical Center)
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Columbia University
New York, New York
University of Rochester Medical Center
Rochester, New York
University of Texas Southwestern
Dallas, Texas
Houston Methodist Research Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.